ProQR to Present at Two Upcoming Investor Conferences in March

LEIDEN, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's congenital amaurosis Type 10 (LCA 10) and dystrophic epidermolysis bullosa (DEB), today announced that Daniel de Boer, Chief Executive Officer, and Smital Shah, Chief Financial Officer, will present during two upcoming investor conferences this month.

A presentation will be given during the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:00am ET. The conference is being held at the Boston Marriott Copley Place in Boston, MA, USA.

The company will also present during the Barclays Global Healthcare Conference on Wednesday, March 15, 2017 at 10:45am ET. The conference is being held at the Loews Miami Beach Hotel in Miami, FL, USA.

The live and archived webcast of both presentations will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcasts will be available for 30 days following the presentation date.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. 
*Since 2012* 

Contact:
Sariette Witte
Investor Relations
T: +1 213 261 8891
ir@proqr.com

You might like this

  • About ProQR Therapeutics

    ProQR was founded by Daniel de Boer with a mission to help people living with rare genetic diseases. This remains the main focus of our company today.

    Daniel de Boer wearing a blue suit stands with arm crossed in a laboratory setting.

  • Axiomer technology - RNA base editing

    A new way to use RNA oligonucleotides to alter RNA, discovered by ProQR. The Axiomer® technology enables the editing of specific single nucleotides in RNA using the cells own editing machinery.

    Axiomer RNA editing platform technology

  • Our science

    Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments for people with severe rare and common diseases.

    ProQR scientist working in the lab